Clinical efficacy of neoadjuvant chemotherapy with irinotecan (CPT-11) and nedaplatin followed by radical hysterectomy for locally advanced cervical cancer.
Clinical efficacy of neoadjuvant chemotherapy with irinotecan (CPT-11) and nedaplatin followed by radical hysterectomy for locally advanced cervical cancer.
复制标题
DOI：
10.1177/0300060515591858
复制
发表时间：
2016-04
期刊：
影响因子：
--
通讯作者：
Konishi I
中科院分区：
文献类型：
--
作者：
Abou-Taleb HA;Koshiyama M;Matsumura N;Baba T;Yamaguchi K;Hamanishi J;Abiko K;Yamanoi K;Murakami R;Horikawa N;Taha AA;Kitamura S;Konishi I
探讨伊立替康（CPT-11）联合奈达铂（NED）新辅助化疗（NAC）后行广泛子宫切除术的临床疗效。局部晚期宫颈癌（Ib 2-IIb期）患者接受NAC治疗，随后接受手术、初次手术或初次放疗。NAC通常采用经子宫动脉化疗（TUAC）或静脉注射CPT-11/NED。分析了三个治疗组的生存率;比较了NAC、TUAC和CPT-11/NED相关的缓解率和不良事件，沿着既往报告的放化疗不良事件。共招募了165名宫颈癌患者。其中，70例接受NAC治疗，随后接受手术治疗（48例接受CPT-11/NED，18例接受TUAC，4例接受其他类型的化疗），73例接受初次手术治疗，22例接受初次放疗（包括放化疗）。三个治疗组之间的无进展生存期或总生存率无显著差异。CPT-11/NED和TUAC的NAC方案的反应率较高（分别为75%和78%）。与TUAC相比，CPT-11/NED患者的重度血小板减少症发生率较低，与放化疗相比，CPT-11/NED患者的重度贫血、呕吐和膀胱炎发生率较低。CPT-11/NED作为NAC方案的使用显示出良好的活性，与使用TUAC或放化疗的NAC相比，毒性较低，用于治疗局部晚期宫颈癌。
To investigate the clinical efficacy of neoadjuvant chemotherapy (NAC) with irinotecan (CPT-11) and nedaplatin (NED) followed by radical hysterectomy. Patients with locally advanced cervical cancer (stage Ib2–IIb) were treated with NAC followed by surgery, primary surgery or primary radiotherapy. NAC was usually performed using transuterine arterial chemotherapy (TUAC) or intravenous CPT-11/NED. Survival rates were analysed in the three treatment groups; response rates and adverse events associated with NAC, TUAC and CPT-11/NED were compared, along with previously reported adverse events of chemoradiotherapy. A total of 165 patients with cervical cancer were recruited. Of these, 70 were treated with NAC followed by surgery (48 with CPT-11/NED, 18 with TUAC and four with other types of chemotherapy), 73 were treated with primary surgery and 22 with primary radiotherapy (including chemoradiotherapy). There were no significant differences in progression-free survival or overall survival rates between the three treatment groups. The response rates for the NAC regimen of CPT-11/NED and TUAC were high (75% and 78%, respectively). The frequency of severe thrombocytopenia was lower in patients receiving CPT-11/NED compared with TUAC, and the incidence of severe anaemia, vomiting and cystitis was lower in patients receiving CPT-11/NED compared with chemoradiotherapy. The use of CPT-11/NED as a NAC regimen shows favourable activity, with lower toxicity compared with NAC using TUAC or chemoradiotherapy, for the treatment of locally advanced cervical cancer.
登录
查看更多内容
影响因子：
4.7
作者：
Le Borgne, Gwenael;Mercier, Mariette;Joly, Florence
通讯作者：
Joly, Florence
影响因子：
3
作者：
Mori, K;Kondo, T;Tominaga, K
通讯作者：
Tominaga, K
影响因子：
3.3
作者：
Ohara, Tatsuru;Kobayashi, Yoichi;Suzuki, Nao
通讯作者：
Suzuki, Nao
DOI：
10.1111/j.1525-1438.2007.00803.x
发表时间：
2007-01-01
影响因子：
4.8
作者：
Ryu, H. -S.;Kang, S. B.;Kim, J. -H.
通讯作者：
Kim, J. -H.
影响因子：
4.7
作者：
Chen, Huijun;Liang, Chuan;Wu, Xufeng
通讯作者：
Wu, Xufeng